CD163在胆道闭锁肝纤维化中的表达及临床意义

doi:10.11958/20221539

天津医药 ›› 2023, Vol. 51 ›› Issue (4): 400-403.doi: 10.11958/20221539

CD163在胆道闭锁肝纤维化中的表达及临床意义

刘志杰¹^,²(), 郑启鹏¹^,², 徐晓丹¹^,², 王琼¹^,², 李梦迪¹^,², 张聪¹^,², 王智茹¹^,², 詹江华²^,^△()

1 天津医科大学研究生院（邮编300070）
2 天津市儿童医院普外科

收稿日期:2022-09-22 修回日期:2022-11-28 出版日期:2023-04-15 发布日期:2023-04-20
通讯作者: 詹江华 E-mail:liuzhijiexj@163.com;zhanjianghuatj@163.com
作者简介:刘志杰（1979），男，主治医师，主要从事小儿外科肝胆疾病方面研究。E-mail：liuzhijiexj@163.com
基金资助:
天津市科技计划项目(21ZXGWSY00070);新疆维吾尔自治区自然科学基金面上项目(2022D01A27)

Expression and clinical significance of CD163 in hepatic fibrosis with biliary atresia

LIU Zhijie¹^,²(), ZHENG Qipeng¹^,², XU Xiaodan¹^,², WANG Qiong¹^,², LI Mengdi¹^,², ZHANG Cong¹^,², WANG Zhiru¹^,², ZHAN Jianghua²^,^△()

1 Graduate School of Tianjin Medical University, Tianjin 300070, China
2 Department of General Surgery, Tianjin Children's Hospital

Received:2022-09-22 Revised:2022-11-28 Published:2023-04-15 Online:2023-04-20
Contact: ZHAN Jianghua E-mail:liuzhijiexj@163.com;zhanjianghuatj@163.com

刘志杰, 郑启鹏, 徐晓丹, 王琼, 李梦迪, 张聪, 王智茹, 詹江华. CD163在胆道闭锁肝纤维化中的表达及临床意义[J]. 天津医药, 2023, 51(4): 400-403.

LIU Zhijie, ZHENG Qipeng, XU Xiaodan, WANG Qiong, LI Mengdi, ZHANG Cong, WANG Zhiru, ZHAN Jianghua. Expression and clinical significance of CD163 in hepatic fibrosis with biliary atresia[J]. Tianjin Medical Journal, 2023, 51(4): 400-403.

摘要/Abstract

摘要：

目的探讨CD163在胆道闭锁（BA）患儿中的表达及其与肝纤维化的关系。方法收集30例BA患儿（BA组，肝纤维化Ⅰ~Ⅱ级14例，Ⅲ~Ⅳ级16例）、10例胆总管囊肿患儿（CC组），获取2组肝组织样本和血液标本。通过免疫组化染色、流式细胞术检测2组肝组织和血液中CD163表达水平。酶联免疫吸附试验检测可溶性CD163（sCD163）表达，受试者工作特征（ROC）曲线分析sCD163评估BA肝纤维化中的价值。结果免疫组化染色和流式细胞术提示，BA组肝组织和血液中CD163表达水平高于CC组（P<0.01），且随着肝纤维化程度增加而升高（P<0.01），sCD163表达亦呈相同变化。sCD163预测BA的ROC曲线下面积为0.927，最佳临界值为8.323 μg/L，敏感度为86.67%，特异度为100%。结论 BA患儿CD163表达上调，加速肝纤维化进程；sCD163能够较准确反映BA患儿肝纤维化严重程度。

关键词: 胆道闭锁, 肝纤维化, CD163

Abstract:

Objective To investigate the expression of CD163 in children with biliary atresia (BA) and its relationship with liver fibrosis. Methods A total of 30 children with BA (the BA group, 14 patients with liver fibrosis grade Ⅰ-Ⅱ, 16 patients with liver fibrosis grade Ⅲ-Ⅳ) and 10 children with choledochal cyst (the CC group) were collected. Samples of liver tissue and blood were obtained from the 2 groups. The expression levels of CD163 in liver tissue and blood of the two groups were detected by immunohistochemistry and flow cytometry. The expression of sCD163 was detected by enzyme-linked immunosorbent assay (ELISA), and the value of sCD163 in evaluating BA liver fibrosis was analyzed by receiver operating characteristic curve (ROC). Results Immunohistochemical staining and flow cytometry indicated that CD163 expression levels in liver tissue and blood were significantly higher in the BA group than those in the CC group (P<0.01), and which increased with the increased severity of liver fibrosis (P<0.01). The expression of sCD163 also showed the same change. sCD163 predicted BA with an area under the ROC curve of 0.927, a best threshold value of 8.323 μg/L, a sensitivity of 86.67% and a specificity of 100%. Conclusion The expression of CD163 is up-regulated in children with BA, which accelerates the process of liver fibrosis. sCD163 can accurately reflect the severity of liver fibrosis in children with BA.

Key words: biliary atresia, hepatic fibrosis, CD163

中图分类号:

R726

图/表 4

图1 IHC检测CC组和BA组肝组织CD163表达（×200）黑色箭头示CD163阳性细胞。

Fig.1 IHC results of CD163 expression in liver tissue of the CC group and the BA group (×200)

图2 FCM检测CC组和BA组血液中CD163表达

Fig.2 FCM results of CD163 expression in blood of the CC group and the BA group

图3 sCD163评估BA肝纤维化ROC曲线

Fig.3 Evaluation of ROC curve of BA liver fibrosis evaluated by sCD163

表1 BAⅠ~Ⅱ级及Ⅲ~Ⅳ级肝纤维化中各肝功能相关生化指标

Tab.1 Biochemical indexes related to liver function in BA grade Ⅰ-Ⅱ and grade Ⅲ~Ⅳ liver fibrosis

组别	n	ALT （U/L）	AST （U/L）	TB （μmol/L）	DB （μmol/L）
Ⅰ~Ⅱ级	14	112（76，149）	165（129，266）	174.0±33.0	141.9±28.3
Ⅲ~Ⅳ级	16	116（96，180）	225（147，303）	166.2±44.6	133.0±31.5
Z或t		0.644	1.102	0.528	0.816

参考文献 20

[1]	UDOMSINPRASERT W, POOVORAWAN Y, CHONGSRISAWAT V, et al. Decreased circulating clusterin reflects severe liver complications after hepatoportoenterostomy of biliary atresia[J]. Sci Rep, 2020, 10(1):19736. doi:10.1038/s41598-020-76875-9.
[2]	詹江华, 李梦迪. 胆道闭锁Kasai术后胆管炎的发病机制探讨[J]. 天津医药, 2022, 50(1):1-4.
	ZHAN J H, LI M D. The study on pathogenesis of cholangitis after Kasai procedure in children with biliary atresia[J]. Tianjin Med J, 2022, 50(1):1-4. doi:10.11958/20211092.
[3]	WANG Y, RAO H, CHI X, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality[J]. EBioMedicine, 2019, 46:227-235. doi:10.1016/j.ebiom.2019.07.043.
[4]	LAURSEN T L, WONG G L, KAZANKOV K, et al. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment[J]. J Gastroenterol Hepatol, 2018, 33(2):484-491. doi:10.1111/jgh.13849.
[5]	GRØNBÆK H, RØDGAARD-HANSEN S, AAGAARD N K, et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)[J]. J Hepatol, 2016, 64(4):813-822. doi:10.1016/j.jhep.2015.11.021.
[6]	丁美云, 詹江华, 刘丹丹, 等. 胆道闭锁肝纤维化分级[J]. 中华小儿外科杂志, 2015, 36(11):866-872.
	DING M Y, ZHAN J H, LIU D D, et al. Grading of hepatic fibrosis in biliary atresia[J]. Chin J Pediatr Surg, 2015, 36(11):866-872. doi:10.3760/cma.j.issn.0253-3006.2015.11.016.
[7]	SHEN W J, CHEN G, WANG M, et al. Liver fibrosis in biliary atresia[J]. World J Pediatr, 2019, 15(2):117-123. doi:10.1007/s12519-018-0203-1.
[8]	BOLTJES A, MOVITA D, BOONSTRA A, et al. The role of Kupffer cells in hepatitis B and hepatitis C virus infections[J]. J Hepatol, 2014, 61(3):660-671. doi:10.1016/j.jhep.2014.04.026.
[9]	陈灵芝, 詹江华, 赵金凤, 等. 磷脂酰肌醇蛋白多糖3对胆道闭锁患儿的诊断价值及与肝纤维化的关系[J]. 天津医药, 2022, 50(1):15-19.
	CHEN L Z, ZHAN J H, ZHAO J F, et al. The diagnostic value of glypican 3 in children with biliary atresia and its relationship with liver fibrosis[J]. Tianjin Med J, 2022, 50(1):15-19. doi:10.11958/20211114.
[10]	余晨, 熊希倩, 詹江华, 等. MMP-7在胆道闭锁肝纤维化患者中的表达及临床意义[J]. 天津医药, 2019, 47(1):38-42.
	YU C, XIONG X Q, ZHAN J H, et al. Expression and clinical significance of MMP-7 in hepatic fibrosis of biliary atresia[J]. Tianjin Med J, 2019, 47(1):38-42. doi:10.11958/20181302.
[11]	ZHAO J, XU X, GOU Q, et al. TGF-β1-mediated leukocyte cell-derived chemotaxin 2 is associated with liver fibrosis in biliary atresia[J]. Front Pediatr, 2022, 10:901888. doi:10.3389/fped.2022.901888.
[12]	DULTZ G, GERBER L, FARNIK H, et al. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus[J]. J Viral Hepat, 2015, 22(4):427-432. doi:10.1111/jvh.12309.
[13]	ZHAO S X, LI W C, FU N, et al. CD14+ monocytes and CD163+ macrophages correlate with the severity of liver fibrosis in patients with chronic hepatitis C[J]. Exp Ther Med, 2020, 20(6):228. doi:10.3892/etm.2020.9358.
[14]	BELJAARS L, SCHIPPERS M, REKER-SMIT C, et al. Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans[J]. Front Immunol, 2014, 5:430. doi:10.3389/fimmu.2014.00430.
[15]	KAZANKOV K, BARRERA F, MØLLER H J, et al. Soluble CD163,a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C[J]. Hepatology, 2014, 60(2):521-530. doi:10.1002/hep.27129.
[16]	GANTZEL R H, KJÆR M B, LAURSEN T L, et al. Macrophage activation markers, soluble CD163 and mannose receptor, in liver fibrosis[J]. Front Med (Lausanne), 2020, 7:615599. doi:10.3389/fmed.2020.615599.
[17]	刘更新, 詹江华. 胆道闭锁诊断方法价值分析[J]. 中华肝胆外科杂志, 2021, 27(3):232-235.
	LIU G X, ZHAN J H. Analysis of diagnostic value of biliary atresia[J]. Chinese Journal of Hepatobiliary Surgery, 2021, 27(3):232-235. doi:10.3760/cma.j.cn113884-20200416-00203.
[18]	CHEN X, DONG R, SHEN Z, et al. Value of gamma-glutamyl transpeptidase for diagnosis of biliary atresia by correlation with age[J]. J Pediatr Gastroenterol Nutr, 2016, 63(3):370-373. doi:10.1097/MPG.0000000000001168.
[19]	LERTUDOMPHONWANIT C, MOURYA R, FEI L, et al. Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia[J]. Sci Transl Med, 2017, 9(417):eaan8462. doi:10.1126/scitranslmed.aan8462.
[20]	SCHREIBER R A. Newborn screening for biliary atresia[J]. JAMA, 2020, 323(12):1137-1138. doi:10.1001/jama.2020.2727.

CD163在胆道闭锁肝纤维化中的表达及临床意义

Expression and clinical significance of CD163 in hepatic fibrosis with biliary atresia

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 4

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩一江, 胡书奇, 陈宝海, 黄寿奖, 秦琪, 吕成杰, 钭金法, △. GGT联合DBIL、APRI对胆道闭锁的诊断价值[J]. 天津医药, 2022, 50(1): 11-14.
[2]	郑启鹏, 李梦迪, 张聪, 陈灵芝, 赵一霖, 杨芳, 刘更新, 詹江华△. EGF-ERK1/2-IL-8通路在胆道闭锁患儿Kasai术后胆管炎中的作用机制研究[J]. 天津医药, 2022, 50(1): 5-10.
[3]	陈灵芝, 詹江华△, 赵金凤, 杨芳, 赵一霖, 林书祥, 马慧, 胡晓丽. 磷脂酰肌醇蛋白多糖3对胆道闭锁患儿的诊断价值及与肝纤维化的关系[J]. 天津医药, 2022, 50(1): 15-19.
[4]	张智鑫, 董冲, 孙超, 吴迪, 张威, 王凯, 高伟△. Kasai术对胆道闭锁患儿肝移植手术及预后的影响[J]. 天津医药, 2022, 50(1): 20-24.
[5]	葛军涛, 詹江华△. 胆道闭锁Kasai术后辅助治疗研究进展[J]. 天津医药, 2022, 50(1): 30-34.
[6]	詹江华, 李梦迪. 胆道闭锁Kasai术后胆管炎的发病机制探讨[J]. 天津医药, 2022, 50(1): 1-4.
[7]	杨仁杰, 张聪, 詹江华△. GATA6抑制肝星状细胞活化在胆道闭锁肝纤维化中的研究进展[J]. 天津医药, 2022, 50(1): 35-40.
[8]	葛亮, 苟庆云, 赵金凤, 张聪, 陈灵芝, 胡晓丽, 詹江华. BMP-9在胆道闭锁肝纤维化中的作用机制研究[J]. 天津医药, 2021, 49(10): 1020-1025.
[9]	葛亮, 苟庆云, 赵金凤, 高伟, 詹江华△. 肝脏CD4、CD8及CD68表达与Kasai术后胆管炎的关系研究[J]. 天津医药, 2020, 48(8): 720-725.
[10]	龙翠珍, 舒远辉, 何萍, 王豫萍, △. 大麻素受体2激动剂AM1241对TGF-β1诱导的HSC-T6增殖、活化及凋亡的影响[J]. 天津医药, 2020, 48(7): 606-610.
[11]	李璨, 陆爽, 吴君. 丹防胶囊对免疫性肝纤维化大鼠肝组织wnt1、β-catenin、DKK1表达的影响[J]. 天津医药, 2019, 47(8): 804-809.
[12]	詹江华△，王立. 胆道闭锁围术期营养状况评价的临床意义[J]. 天津医药, 2019, 47(4): 342-345.
[13]	詹江华 1△，余晨 2. 病毒疫苗对预防胆道闭锁的可行性探讨[J]. 天津医药, 2019, 47(4): 339-342.
[14]	张辉 1，林松 2，熊希倩 3，闫学强 3，余晨 3，高伟 4，胡晓丽 5，赵丽 5，詹江华 1△. 胆管板畸形对胆道闭锁患儿自体肝生存的影响[J]. 天津医药, 2019, 47(4): 346-350.
[15]	葛亮 1，詹江华 2△，高伟 3，余晨 1，赵升桥 1，徐晓丹 1，窦然 1. 胆道闭锁Kasai术后早期行肝移植手术的危险因素分析[J]. 天津医药, 2019, 47(4): 351-355.